<DOC>
	<DOC>NCT01903837</DOC>
	<brief_summary>This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.</brief_summary>
	<brief_title>A Study of ALKS 3831 in Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Age 18 to 50 years, inclusive Body mass index (BMI) of 1730 kg/m2, inclusive Diagnosis of schizophrenia that is clinically stable Initiated 1st antipsychotic treatment within the past 12 months and/or has had symptoms lasting &lt;2 years Current diagnosis of alcohol or drug use disorder, moderate or severe Clinically significant or unstable medical illness, condition, or disorder Pregnant or breastfeeding Significant changes in diet or exercise regimen or plans to join a weight management program during the study Opioid medications taken within 14 days and/or need to take opioid medication during the study period History of hypersensitivity to or intolerance of olanzapine Use of olanzapine, clozapine, mesoridazine, chlorpromazine, or thioridazine for more than 1 week during the past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Alkermes</keyword>
</DOC>